Who is sponsoring NCT04782089?

NCT04782089 is sponsored by Qilu Hospital of Shandong University.

What drugs are being tested in NCT04782089?

Interventions in NCT04782089: Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors.

What condition does NCT04782089 study?

NCT04782089 studies Small Cell Lung Cancer.

Is NCT04782089 still recruiting?

NCT04782089 is currently status unknown. Last updated 4 March 2021.

Last reviewed 2021-03-04 · How we verify

NCT04782089

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Status unknown NA Last updated 4 March 2021

What this trial tests

NA trial testing Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors in Small Cell Lung Cancer in 20 participants. Status unknown.

Timeline

6 May 2021

Primary endpoint
1 May 2023

1 June 2024

Quick facts

Lead sponsor	Qilu Hospital of Shandong University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	6 May 2021
Primary completion	1 May 2023
Estimated completion	1 June 2024

Drugs / interventions tested

Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors — full drug profile →

Conditions studied

Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →

Sponsor

Qilu Hospital of Shandong University

Who can join

Adults 18 to 75, any sex, with Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase II, Open, Single-center Study of Camrelizumab and Fluzoparib as Consolidation Treatment for Patients With Extensive stage small cell lung cancer Who Have Not Progressed after first-line treatment

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
Taniguchi H, Caeser R, Chavan SS, Zhan YA, et al · · 2022 · cited 91× · PMID 35584676 · DOI 10.1016/j.celrep.2022.110814
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K. · · 2022 · cited 56× · PMID 35435784 · DOI 10.1080/13543784.2022.2067527
Novel Therapeutic Options for Small Cell Lung Cancer.
Canova S, Trevisan B, Abbate MI, Colonese F, et al · · 2023 · cited 13× · PMID 37870696 · DOI 10.1007/s11912-023-01465-7
First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy.
Giunta EF, Addeo A, Rizzo A, Banna GL. · · 2022 · cited 10× · PMID 35692538 · DOI 10.3389/fmed.2022.924853
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities.
Zhang J, Zeng X, Guo Q, Sheng Z, et al · · 2024 · cited 8× · PMID 39103941 · DOI 10.1186/s40164-024-00548-w
Genome instability and crosstalk with the immune response.
Chabanon RM, Danlos FX, Ouali K, Postel-Vinay S. · · 2025 · cited 4× · PMID 41188872 · DOI 10.1186/s13073-025-01509-6
Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities.
Tiwari A, Kumari B, Nandagopal S, Mishra A, et al · · 2024 · PMID 38473324 · DOI 10.3390/cancers16050963

Verify or expand the search:

Other recruiting trials for Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Other Qilu Hospital of Shandong University trials

Trials by the same sponsor.

NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
NCT07140419 — Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients. · NA · not yet recruiting
NCT07509879 — Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder · not yet recruiting
NCT07537374 — A Case-Control Observational Study of Peripheral Blood-Derived iPSC Models to Investigate Oligodendrocyte Lineage Develo · not yet recruiting
NCT07505940 — Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04782089 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qilu Hospital of Shandong University
Last refreshed: 4 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04782089.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing